The global diabetic macular edema market is expected to reach a valuation of US$3.7 billion by the end of 2022, according to market research firm FMI. While the projected Compound Annual Growth Rate (CAGR) from 2022 to 2032 is modest at 1.2%, reaching approximately US$4.2 billion by the end of the forecast period, the market presents significant opportunities for future growth.
Preview Next-Level Insights Sample : https://www.futuremarketinsights.com/reports/sample/rep-gb-2697
Escalating Diabetes Rates: A Double-Edged Sword
The primary driver for the DME market is the rising global prevalence of type 2 diabetes. The World Health Organization reports a staggering 422 million people living with the condition in 2014, and this number is only expected to climb. This alarming rise in diabetes diagnoses translates to a growing pool of individuals susceptible to DME, a common and sight-threatening complication of the disease.
Market Growth Despite Challenges
Despite the increasing number of potential DME patients, the DME market growth is expected to be moderate. This can be attributed to factors such as:
- Management Strategies: Advancements in diabetes management, including improved blood sugar control, can help prevent DME development.
- Treatment Landscape: The current standard of care for DME, anti-VEGF medications, is highly effective in managing the condition. However, the need for frequent injections can be a burden for some patients.
Future Opportunities
The DME market holds promise for future growth due to several exciting trends:
- Emerging Therapies: The development of new and longer-acting anti-VEGF drugs, along with gene therapies, promises to improve treatment efficacy and potentially reduce treatment burden.
- Focus on Early Detection: Early diagnosis and intervention remain crucial in preventing vision loss from DME. Increased awareness and improved screening methods can significantly impact patient outcomes.
Obtain Methodology Information: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-2697
Key Companies Profiled:
- Novartis AG
- Bayer AG
- Allergan Plc.
- F. Hoffmann-La Roche Ltd.
- Alimera Sciences Inc.
- Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Inc.)
- KalVista Pharmaceuticals
- Genentech
- Oxurion (fka ThromboGenics)
- Ocugen, Inc
- Regeneron Pharmaceuticals, Inc.
- Clearside Biomedical
- Daiichi Sankyo
- Arctic Vision
- Chugai Pharmaceutical Co., Ltd.
Get Full Market Analysis Now: Purchase Now to Access: https://www.futuremarketinsights.com/checkout/2697
Key Segments Covered In Diabetic Macular Edema Market Report:
By Drug:
- Anti-VEGF
- Ranibizumab (Lucentis)
- Aflibercept (Eylea)
- Corticosteroid Therapies
- Dexamethasone (Ozurdex)
- Fluocinolone Acetonide (Iluvien)
- Other Off-label Drugs
By Form:
- Intravitreal Injections
- Intravitreal Implants
By Distribution Channel:
- Hospitals
- Specialty Clinics
- Mail Order Pharmacies
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
